Massive COPD study aims to unlock secrets of lung disease
NCT ID NCT01969344
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows nearly 3,000 people with COPD (a chronic lung disease) over several years to understand how the disease progresses and what factors influence it. Researchers measure lung function, analyze mucus, and track environmental exposures like air pollution. The goal is to find better ways to predict and measure COPD worsening, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
2,981 people
The number who actually took part.
- Start date
-
Nov 2010
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Never-smokers, current and former smokers without COPD, and current and former smokers with COPD with access to one of the study clinical centers.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Between 40 and 80 at baseline visit * Never smokers: \<1 pack-year history of smoking * Never smokers: Must meet lung function criteria based on spirometry without inhaled bronchodilators * Current or former smokers: \>20 pack-year history of smoking * Current or former smokers: Must meet lung function criteria based on spirometry with inhaled bronchodilators Exclusion Criteria: * Dementia or other cognitive dysfunction which in the opinion of the investigator would prevent the participant from consenting to the study or completing study procedures * Plans to leave the area in the next 3 years * Smoking history of \> 1 pack-year but \<21 pack-years * BMI \> 40 kg/m2 at baseline exam * Prior significant difficulties with pulmonary function testing * Hypersensitivity to or intolerance of albuterol sulfate or ipratropium bromide or propellants or excipients of the inhalers * Non-COPD obstructive lung disease, severe kyphoscoliosis, neuromuscular weakness, or other conditions, including clinically significant cardiovascular and pulmonary disease, that, limit the interpretability of the pulmonary function measures. * History of Interstitial lung disease * History of Lung volume reduction surgery or lung resection * History of lung or other organ transplant * History of endobronchial valve therapy * History of large thoracic metal implants (e.g., AICD (automatic implantable cardioverter/defibrillator) and/or pacemaker) * Currently taking \>=10mg a day/20mg every other day of prednisone or equivalent systemic corticosteroid * Currently taking any immunosuppressive agent * Current illicit substance abuse, excluding marijuana * History of or current use of IV Ritalin * History of or current use of heroin * History of illegal IV drug use within the last 10 years or more than 5 instances of illegal IV drug use ever * Known HIV/AIDS infection * History of lung cancer or any cancer that spread to multiple locations in the body * History of or current exposure to chemotherapy or radiation treatments that, in the opinion of the investigator, limits the interpretability of the pulmonary function measures. * Diagnosis of unstable cardiovascular disease including myocardial infarction in the past 6 weeks, uncontrolled congestive heart failure, or uncontrolled arrhythmia * Any illness expected to cause mortality in the next 3 years * Active pulmonary infection, including tuberculosis * History of pulmonary embolism in the past 2 years * Known diagnosis of primary bronchiectasis * Currently institutionalized (e.g., prisons, long-term care facilities) * Known to be a first degree relative of another, already enrolled participant (i.e., biological parent, biological sibling) * Never smokers only: Current diagnosis of asthma * Women only: Cannot be pregnant at baseline or plan to become pregnant during the course of the study Temporal Exclusion Criteria for SPIROMICS III: * Participants who present with a pulmonary exacerbation, either solely participant-identified or that has been clinically treated, in the last six weeks, can complete the study visit once a six-week window has passed. * Participants who present with an upper respiratory infection, either solely participant-identified or that has been clinically treated, in the last six weeks, can complete the study visit once a six-week window has passed. * Participants who present with current use of acute antibiotics or steroids can complete the study visit ≥30 days after discontinuing acute antibiotics/steroids. This does not apply to participants who are on chronic prednisone therapy of \<10 mg per day or \<20 mg every other day or participants who are currently on chronic, prophylactic, or suppressive antibiotic therapy. * Participants who present with a myocardial infarction or eye, chest or abdominal surgery within six weeks can complete the study visit after a six-week window has passed. * Female participants who present \<3 months after giving birth will be asked to schedule the visit once three months have passed post-delivery.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic bronchitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University
New York, New York, 10032, United States
-
Johns Hopkins University
Baltimore, Maryland, 21224, United States
-
Mayo Clinic Arizona
Scottsdale, Arizona, 85259, United States
-
National Jewish Health
Denver, Colorado, 80206, United States
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
University of California at Los Angeles
Los Angeles, California, 90095, United States
-
University of California at San Francisco
San Francisco, California, 94143, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
-
Wake Forest University
Winston-Salem, North Carolina, 27157, United States
-
Weill Cornell Medicine
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a COPD flare stun the heart? study watches for hidden strain
- Tiny One-Way valves for emphysema under close watch in japan
- One-Way valves in the lung: can they help emphysema patients breathe easier?
- Can better training get doctors to talk about what matters most to dying veterans?
- Is RSV a hidden driver of severe COPD attacks?